Evidence map›Paper›PMID 25506224›Full record

ArticleOncoTargets and therapy2014

EGF and EGFR genetic polymorphisms predict prognosis in locally advanced pharyngolaryngeal squamous cell carcinoma patients receiving postoperative concurrent chemoradiotherapy.

Nai-Wen Su, Yi-Shing Leu, Jehn-Chuan Lee, Chung-Ji Liu, Chieh-Yuan Cheng, Jiun-Sheng Lin, Yu-Jen Chen, Chi-Kuan Chen, I-Chih Fang, Ruey-Kuen Hsieh and 1 more

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Gene polymorphisms and prognosis of head and neck squamous cell carcinoma: a systematic review.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022
    Review
  4. Polymorphisms inInternational journal of molecular sciences · 2021
    Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Nai-Wen SuDivision of Medical Oncology and Hematology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan.
Yi-Shing LeuDepartment of Otorhinolaryngology, Mackay Memorial Hospital, Taipei, Taiwan.
Jehn-Chuan LeeDepartment of Otorhinolaryngology, Mackay Memorial Hospital, Taipei, Taiwan.
Chung-Ji LiuDepartment of Oral and Maxillofacial Surgery, Mackay Memorial Hospital, Taipei, Taiwan.
Chieh-Yuan ChengDepartment of Oral and Maxillofacial Surgery, Mackay Memorial Hospital, Taipei, Taiwan.
Jiun-Sheng LinDepartment of Oral and Maxillofacial Surgery, Mackay Memorial Hospital, Taipei, Taiwan.
Yu-Jen ChenDepartment of Radiation Oncology, Mackay Memorial Hospital, Taipei, Taiwan.
Chi-Kuan ChenDepartment of Pathology, Mackay Memorial Hospital, Taipei, Taiwan.
I-Chih FangGood Clinical Research Center, Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan.
Ruey-Kuen HsiehDivision of Medical Oncology and Hematology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan.
Yi-Fang ChangDivision of Medical Oncology and Hematology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan ; Good Clinical Research Center, Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan.
Mackay Memorial Hospital · TWNational Medical Research Center of Dentistry and Maxillofacial Surgery · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpidermal growth factor (EGF) and its receptor (EGFR) are part of an important signaling pathway that is involved in the pathogenesis of squamous cell carcinoma of the head and neck (SCCHN). We hypothesized that EGF/EGFR genetic polymorphisms might have a prognostic impact on disease-free survival and overall survival (OS) in locally advanced SCCHN. MATERIALS AND

methodsThe patient group included a consecutive cohort of 180 patients with locally advanced SCCHN who underwent postoperative concurrent chemoradiotherapy between 2002 and 2010. DNA from formalin-fixed, paraffin-embedded tumor tissues was genotyped for the single nucleotide polymorphism (SNP) of EGF A61G A>G, EGFR R521K G>A and G-216T. The log-rank test was applied to evaluate the impact of SNPs on the outcomes. Survival was estimated using the Kaplan-Meier statistical method.

resultsWe demonstrated that EGF/EGFR SNPs might predict prognosis in patients with primary pharyngolaryngeal tumors, but not in those with oral cavity tumors. In pharyngolaryngeal tumor subgroup, EGF61 G/G genotype led to worse 5 year OS rate when compared to G/A or A/A genotypes (13.3% versus 34.3% versus 50.0%, P=0.017). The 5 year OS of patients with EGFR R521K G/G (11.1%) and G/A (15.9%) were lower than the A/A (62.5%) genotype (P=0.054). Patients carrying one or two unfavorable alleles had worse 5 year OS than those without unfavorable allele (not available versus 20% versus 71.4%, P=0.002). Multivariate analysis revealed that the highest risk of death was associated with the coexistence of two unfavorable genotypes (hazard ratio 25.7, 95% confidence interval =3.4-193.4; P=0.002).

conclusionIn this study, we were able to demonstrate that the EGF A61G and EGFR R521K genetic polymorphisms might be important prognostic factors in patients with locally advanced primary pharyngolaryngeal squamous cell carcinoma who underwent postoperative concurrent chemoradiotherapy.

Indexed as

biomarkerEGF A61GEGFR R521Khead and neck cancerpolymorphisms

Identifiers

PMID25506224
PMCPMC4259259
OpenAlexW2088957001

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.